Shots:
- AstraZeneca has reported P-III (CARES) trial findings assessing anselamimab (QW for 4wks. then Q2W till completion) + SoC vs PBO + SoC in pts (N=406) with stage IIIa (n=281) & stage IIIb (n=125) light chain (AL) amyloidosis
- Trial did not meet its 1EP of time to all-cause mortality & frequency of CV hospitalisations. However, anselamimab showed a highly clinically meaningful benefit in a prespecified subgroup, with full results under ongoing evaluation & to be shared with global health authorities & in a future meeting
- Anselamimab is an anti-fibril monoclonal antibody designed to improve organ function in AL amyloidosis by selectively targeting misfolded amyloid fibrils for clearance while sparing native free light chains
Ref: Astrazeneca | Image: Astrazeneca | Press Release
Related News:- AstraZeneca Reports P-III (BaxHTN) Trial Results of Baxdrostat for Uncontrolled or Treatment Resistant Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
